Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigious | ||
| Readability |
H.S. senior Avg
|
|
New words:
acknowledging, adjunctive, AI, amortizable, ANDA, appetite, ataxia, ATM, attached, automated, bexotegrast, bezafibrate, bilirubin, bioequivalence, bona, boost, Cantor, CASL, cheaper, chenodeoxycholic, chenodiol, cholic, COMP, Cooley, Cosmetic, CTX, delete, digit, disorder, disturbance, EC, enzyme, ethical, evade, Exhibit, FADP, Falk, fashion, fatigue, fide, Fitzgerald, forensic, forthcoming, gait, gallbladder, HTA, infection, interdependently, intestinal, jaundice, Leadiant, Leerink, lesion, LLP, main, malaise, margin, necessity, neuropathy, obfuscate, Parliament, peripheral, peroxisomal, peroxisome, pharmacovigilance, polyp, provincial, psychiatric, radiolucent, reflux, resale, resold, RMP, skin, spectrum, suit, tract, transforming, urinary, USD, version
Filing tables
Filing exhibits
Related press release
Associated MIRM transcripts
MIRM similar filings
Filing view
External links
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Mirum Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the quarter ended September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)
The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: November 2, 2023 | By: | /s/ Eric Bjerkholt | |
Erik Bjerkholt | |||
Chief Financial Officer (Principal Financial Officer) |